/PRNewswire/ Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI.
UPPSALA, Sweden, April 27, 2022 /PRNewswire/ Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company's partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248)
Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.